19:41 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Fast Track designation for Curis' lymphoma therapy

Curis Inc. (NASDAQ:CRIS) said FDA granted Fast Track designation to fimepinostat (formerly CUDC-907) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in a third-line setting. The product is an oral dual phosphoinositide...
00:34 , Mar 10, 2017 |  BC Extra  |  Financial News

Curis secures $45M loan tied to royalties

Curis Inc. (NASDAQ:CRIS) gained $0.53 (21%) to $3.08 on Thursday after reporting earnings and revealing a royalty financing deal with HealthCare Royalty Partners . The biotech is to receive a $45 million loan from HCR,...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

CUDC-907: Additional Phase I data

Data from 10 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in an open-label, dose-escalation, U.S. Phase I trial showed that CUDC-907 led to 2 complete responses and 4 partial responses,...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

CUDC-907 regulatory update

FDA granted Orphan Drug designation to CUDC-907 from Curis to treat diffuse large B cell lymphoma (DLBCL). Next half, Curis plans to begin a Phase II trial of the dual phosphoinositide 3-kinase (PI3K) and histone...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

CUDC-907: Phase I started

Curis began an open-label, U.S. Phase I trial to evaluate 3 dosing schedules of oral CUDC-907 in about 60 patients, including those with hormone receptor-positive, HER2-negative breast cancer or midline carcinoma with rearrangements in the...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

CUDC-907: Preliminary Phase I data

Preliminary data from 11 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that oral CUDC-907 led to a partial response in 1 patient with mixed follicular lymphoma/diffuse large B cell lymphoma (DLBCL),...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

CUDC-907: Phase I started

Curis began an open-label, dose-escalation, U.S. Phase I trial evaluating 30-180 mg oral CUDC-907 once daily in 21-day cycles in about 36 patients with relapsed or refractory lymphoma or MM. The trial includes a MTD...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Curis, LLS deal

Curis received two milestone payments totalling $750,000 from the society under a 2011 deal to develop Curis' CUDC-907 in B cell lymphoma and multiple myeloma (MM). The payments were triggered by the completion of preclinical...
07:00 , Oct 11, 2012 |  BC Innovations  |  Strategy

Leukemia team building

The Leukemia & Lymphoma Society has announced its first research partnership with a large biopharma company-a four-year, multimillion-dollar deal with Celgene Corp. to solicit and fund proposals from academics and smaller biotechs. The not-for-profit organization...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

Curis preclinical data

In mouse xenograft models of cancer, 50 mg/kg IV CUDC-907 and 100 mg/kg oral CUDC-907 both led to stable disease in models of diffuse large B cell lymphoma (DLBCL) and non-small cell lung cancer (NSCLC)....